Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
About Us
Careers
Conferences
Videos
Webinars
Press Releases
Whitepapers
Advertising
Top Story
FDA Warning Letter
FDA issues warning for Cue Health COVID-19 tests
The U.S. Food and Drug Administration (FDA) issued a warning to consumers and healthcare providers not to use Cue Health's COVID-19 over-the-counter test and its COVID-19 test intended for point-of-care settings due to an increased risk of false results.
Featured
Emerging Technology
Biomarker extraction through ultrasound shows promise for cancer detection
Trends and Finance
Northwell Health Cancer Institute opens molecular diagnostics laboratory
Latest News
Danaher launches collaboration with Johns Hopkins University on TBI diagnostics
May 9, 2024
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
Biodesix reports doubling lung nodule testing activity
May 10, 2024
University of Florida researchers develop CRISPR-based assay for HPV detection
May 7, 2024
Business Insights
Emerging Technology
BioMarin confirms layoffs and R&D cuts
FDA Warning Letter
FDA issues warning for Cue Health COVID-19 tests
Trends and Finance
Northwell Health Cancer Institute opens molecular diagnostics laboratory
FDA Clearance
Qiagen gets FDA clearance for respiratory syndromic testing panel
Diagnostic Technologies
Trends and Finance
Northwell Health Cancer Institute opens molecular diagnostics laboratory
FDA Clearance
Qiagen gets FDA clearance for respiratory syndromic testing panel
PCR
Qiagen partners with FBI on forensics assay
Immunoassays
University of Florida researchers develop CRISPR-based assay for HPV detection
Diseases
Emerging Technology
Biomarker extraction through ultrasound shows promise for cancer detection
Emergency Use Authorization
iHealth gets EUA for combination COVID-19/influenza at-home test
Concussion
Danaher launches collaboration with Johns Hopkins University on TBI diagnostics
Immunoassays
University of Florida researchers develop CRISPR-based assay for HPV detection
More from LabPulse.com
Astellas and Poseida to collaborate on oncology cell therapies
By
LabPulse.com staff writers
Poseida Therapeutics and Astellas, under its Xyphos Biosciences subsidiary, have initiated a research collaboration and licensing agreement to develop allogeneic cell therapy programs by combining their innovative cell therapy platforms and technologies.
May 2, 2024
FDA releases LDT final rule
By
Liz Carey
The FDA announced its final rule on regulating laboratory developed tests (LDTs), also saying it will adopt targeted enforcement discretion for several categories of IVD LDTs manufactured by labs.
April 29, 2024
GSK, Genomics PLC collaborate on polygenic risk score use for clinical trials
By
LabPulse.com staff writers
Genomics PLC and biopharmaceutical firm GSK have established a collaboration aimed at assessing the potential for using polygenic risk scores in clinical trials.
May 1, 2024
Variantyx raises $36M in funding
By
LabPulse.com staff writers
Precision molecular diagnostics firm Variantyx has raised $36 million in a recent funding round, bringing the total funding that Variantyx has raised to more than $125 million.
April 30, 2024
Study: Age-related differences in nasal cells offer COVID-19 protection
By
Matt Limb
Key differences in how the nasal cells of young and elderly people respond to the SARS-CoV-2 virus may explain why children typically experience milder symptoms of COVID-19, say researchers.
April 29, 2024
Pillar Biosciences gets FDA approval for NGS solid tumor profiling test
By
Matt Limb
Pillar Biosciences has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its OncoReveal CDx pan-cancer next-generation sequencing (NGS) test for general solid tumor profiling.
April 26, 2024
Immunovia announces positive results for next-gen pancreatic cancer test
By
LabPulse.com staff writers
Diagnostics company Immunovia announced positive results for the newest generation of its pancreatic cancer test from a model-development study, announcing that the test achieved both its primary and secondary endpoints.
April 25, 2024
Vertex to pay $25M upfront to scale cell manufacturing technology
By
LabPulse.com staff writers
As part of the deal, Vertex was also willing to pay up to $215 million in milestones achieved in connection with the development of a scaled-up process for fully differentiated islet cells.
April 25, 2024
Labcorp buys Invitae portfolio for $239M
By
LabPulse.com staff writers
Labcorp was the winning bidder in the court-supervised auction of Invitae's assets, obtaining substantially all of the San Francisco-based company's business for $239 million in cash consideration with other noncash consideration.
April 26, 2024
Bristol Myers Squibb to reduce workforce in restructuring plan
By
LabPulse.com staff writers
As part of a restructuring plan intended to cut $1.5 billion in costs, Bristol Myers Squibb plans to cut about 6% of its workforce, according to the firm.
April 25, 2024
U.K. Patents Court rules Bio-Techne patents invalid in infringement lawsuit
By
LabPulse.com staff writers
The Patents Court of the High Court of England and Wales has ruled that two patents owned by Bio-Techne are invalid, rejecting a patent infringement lawsuit filed by Bio-Techne/ACD in the U.K. against Molecular Instruments.
April 24, 2024
Scout secures CARB-X grant to advance diagnostic test development
By
LabPulse.com staff writers
Scout, formerly Uh Oh Labs, will advance its point-of-care (POC) diagnostic test for sexually transmitted infections (STIs) with a new $1 million accelerator grant.
April 22, 2024